Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LivaNova PLCLIVN · Entity 507 | Chief Legal Officer | September 15, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LivaNova PLC
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 6,291 |
Reported balance
After 2026-09-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 6,291 · Balance 6,291 F1: On September 15, 2026, reporting person was granted 6,291 restricted stock units (RSUs) of LivaNova PLC (the Company) pursuant to the Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the Second A&R 2022 Plan) and the award agreement. The RSUs vest 20% on March 30, 2027 (pro-rated for service from the grant date to such vesting date), 40% on March 30, 2028, and 40% on March 30, 2029. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Second A&R 2022 Plan and the award agreement. F2: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the Second A&R 2022 Plan and the award agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 15, 2026, reporting person was granted 6,291 restricted stock units (RSUs) of LivaNova PLC (the Company) pursuant to the Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the Second A&R 2022 Plan) and the award agreement. The RSUs vest 20% on March 30, 2027 (pro-rated for service from the grant date to such vesting date), 40% on March 30, 2028, and 40% on March 30, 2029. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Second A&R 2022 Plan and the award agreement.
F2: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the Second A&R 2022 Plan and the award agreement.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HOLOGIC INC
Report date April 07, 2026 · Filed April 09, 2026
Section 16 reporting ended · disclosed 2026-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Disposition to issuer · Disposed 28,052 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F2: At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and each Company RSU held by the reporting person granted after October 21, 2025 converted into, for each share of Company Common Stock subject to such Company RSU immediately prior to the Effective Time, (i) an unvested award representing the right to receive a cash payment equal to the Cash Consideration, and (ii) an unvested award representing the right to receive cash payments equal to the payments to the holder of one CVR, if any, pursuant to the CVR agreement, in each case, subject to the terms applied to the corresponding Company RSU immediately prior to the Effective Time. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.61 · Expires 2029-11-11 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-07 · Disposition to issuer · Disposed 2,173 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.35 · Expires 2030-11-09 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Disposition to issuer · Disposed 6,129 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.13 · Expires 2031-11-08 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-07 · Disposition to issuer · Disposed 5,943 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.35 · Expires 2032-11-07 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-07 · Disposition to issuer · Disposed 5,121 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.94 · Expires 2033-11-14 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-07 · Disposition to issuer · Disposed 6,016 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.39 · Expires 2034-11-11 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-07 · Disposition to issuer · Disposed 7,479 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.39 · Expires 2035-03-01 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-07 · Disposition to issuer · Disposed 4,683 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,452 |
Reported balance
After 2026-04-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-07 · Grant · Acquired 3,452 · Balance 3,452 F4: Each Hologic restricted stock unit represents a contingent right to receive one share of Company Common Stock. F5: Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of Company Common Stock subject to each PSU, any applicable performance goals were deemed achieved at the greater of (A) the target level of performance and (B) the actual level of performance measured through the latest practicable date prior to the Effective Time. Pursuant to the Merger Agreement, each outstanding PSU was cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such PSU. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-07 · Disposition to issuer · Disposed 3,452 · Balance 0 F4: Each Hologic restricted stock unit represents a contingent right to receive one share of Company Common Stock. F5: Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of Company Common Stock subject to each PSU, any applicable performance goals were deemed achieved at the greater of (A) the target level of performance and (B) the actual level of performance measured through the latest practicable date prior to the Effective Time. Pursuant to the Merger Agreement, each outstanding PSU was cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such PSU. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").
F2: At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and each Company RSU held by the reporting person granted after October 21, 2025 converted into, for each share of Company Common Stock subject to such Company RSU immediately prior to the Effective Time, (i) an unvested award representing the right to receive a cash payment equal to the Cash Consideration, and (ii) an unvested award representing the right to receive cash payments equal to the payments to the holder of one CVR, if any, pursuant to the CVR agreement, in each case, subject to the terms applied to the corresponding Company RSU immediately prior to the Effective Time. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
F3: For Footnote (3), see Remarks below.
F4: Each Hologic restricted stock unit represents a contingent right to receive one share of Company Common Stock.
F5: Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of Company Common Stock subject to each PSU, any applicable performance goals were deemed achieved at the greater of (A) the target level of performance and (B) the actual level of performance measured through the latest practicable date prior to the Effective Time. Pursuant to the Merger Agreement, each outstanding PSU was cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such PSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 16, 2026 20:23 UTC | LivaNova PLC LIVN · Entity 507 | GrantRestricted Stock Units · Derivative | 6,291 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000106 · wk-form4_1789590197.xml · derivative · entry 1 Liddy Anne M. · CIK 0002061422 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,291 Underlying: Ordinary Shares · 6,291 shares Expires not disclosed F1 · derivative.exercise_date: On September 15, 2026, reporting person was granted 6,291 restricted stock units (RSUs) of LivaNova PLC (the Company) pursuant to the Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the Second A&R 2022 Plan) and the award agreement. The RSUs vest 20% on March 30, 2027 (pro-rated for service from the grant date to such vesting date), 40% on March 30, 2028, and 40% on March 30, 2029. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Second A&R 2022 Plan and the award agreement. F1 · derivative.expiration_date: On September 15, 2026, reporting person was granted 6,291 restricted stock units (RSUs) of LivaNova PLC (the Company) pursuant to the Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the Second A&R 2022 Plan) and the award agreement. The RSUs vest 20% on March 30, 2027 (pro-rated for service from the grant date to such vesting date), 40% on March 30, 2028, and 40% on March 30, 2029. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Second A&R 2022 Plan and the award agreement. F2 · derivative.underlying_shares: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the Second A&R 2022 Plan and the award agreement. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:27 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerPerformance Stock Units · Derivative | 3,452 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000859737-26-000083 · form4.xml · derivative · entry 10 Liddy Anne M. · CIK 0002061422 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,452 shares Expires not disclosed F4 · derivative.exercise_price: Each Hologic restricted stock unit represents a contingent right to receive one share of Company Common Stock. F5 · price: Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of Company Common Stock subject to each PSU, any applicable performance goals were deemed achieved at the greater of (A) the target level of performance and (B) the actual level of performance measured through the latest practicable date prior to the Effective Time. Pursuant to the Merger Agreement, each outstanding PSU was cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such PSU. F5 · derivative.exercise_date: Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of Company Common Stock subject to each PSU, any applicable performance goals were deemed achieved at the greater of (A) the target level of performance and (B) the actual level of performance measured through the latest practicable date prior to the Effective Time. Pursuant to the Merger Agreement, each outstanding PSU was cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such PSU. F5 · derivative.expiration_date: Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of Company Common Stock subject to each PSU, any applicable performance goals were deemed achieved at the greater of (A) the target level of performance and (B) the actual level of performance measured through the latest practicable date prior to the Effective Time. Pursuant to the Merger Agreement, each outstanding PSU was cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such PSU. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:27 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantPerformance Stock Units · Derivative | 3,452 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000859737-26-000083 · form4.xml · derivative · entry 9 Liddy Anne M. · CIK 0002061422 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,452 Underlying: Common Stock · 3,452 shares Expires not disclosed F4 · derivative.exercise_price: Each Hologic restricted stock unit represents a contingent right to receive one share of Company Common Stock. F5 · price: Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of Company Common Stock subject to each PSU, any applicable performance goals were deemed achieved at the greater of (A) the target level of performance and (B) the actual level of performance measured through the latest practicable date prior to the Effective Time. Pursuant to the Merger Agreement, each outstanding PSU was cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such PSU. F5 · derivative.exercise_date: Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of Company Common Stock subject to each PSU, any applicable performance goals were deemed achieved at the greater of (A) the target level of performance and (B) the actual level of performance measured through the latest practicable date prior to the Effective Time. Pursuant to the Merger Agreement, each outstanding PSU was cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such PSU. F5 · derivative.expiration_date: Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of Company Common Stock subject to each PSU, any applicable performance goals were deemed achieved at the greater of (A) the target level of performance and (B) the actual level of performance measured through the latest practicable date prior to the Effective Time. Pursuant to the Merger Agreement, each outstanding PSU was cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such PSU. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:27 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 4,683 | Not disclosed Strike: $63.39 | Not disclosed |
DisclosureSEC source: 0000859737-26-000083 · form4.xml · derivative · entry 8 Liddy Anne M. · CIK 0002061422 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,683 shares Expires 2035-03-01 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:27 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 7,479 | Not disclosed Strike: $79.39 | Not disclosed |
DisclosureSEC source: 0000859737-26-000083 · form4.xml · derivative · entry 7 Liddy Anne M. · CIK 0002061422 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,479 shares Expires 2034-11-11 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:27 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 6,016 | Not disclosed Strike: $71.94 | Not disclosed |
DisclosureSEC source: 0000859737-26-000083 · form4.xml · derivative · entry 6 Liddy Anne M. · CIK 0002061422 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,016 shares Expires 2033-11-14 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:27 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 5,121 | Not disclosed Strike: $74.35 | Not disclosed |
DisclosureSEC source: 0000859737-26-000083 · form4.xml · derivative · entry 5 Liddy Anne M. · CIK 0002061422 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,121 shares Expires 2032-11-07 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:27 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 5,943 | Not disclosed Strike: $71.13 | Not disclosed |
DisclosureSEC source: 0000859737-26-000083 · form4.xml · derivative · entry 4 Liddy Anne M. · CIK 0002061422 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,943 shares Expires 2031-11-08 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:27 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 6,129 | Not disclosed Strike: $68.35 | Not disclosed |
DisclosureSEC source: 0000859737-26-000083 · form4.xml · derivative · entry 3 Liddy Anne M. · CIK 0002061422 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,129 shares Expires 2030-11-09 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:27 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 2,173 | Not disclosed Strike: $45.61 | Not disclosed |
DisclosureSEC source: 0000859737-26-000083 · form4.xml · derivative · entry 2 Liddy Anne M. · CIK 0002061422 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,173 shares Expires 2029-11-11 F3 · price: For Footnote (3), see Remarks below. F3 · derivative.exercise_date: For Footnote (3), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:27 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerCommon Stock | 28,052 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000859737-26-000083 · form4.xml · nonDerivative · entry 1 Liddy Anne M. · CIK 0002061422 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F2 · price: At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and each Company RSU held by the reporting person granted after October 21, 2025 converted into, for each share of Company Common Stock subject to such Company RSU immediately prior to the Effective Time, (i) an unvested award representing the right to receive a cash payment equal to the Cash Consideration, and (ii) an unvested award representing the right to receive cash payments equal to the payments to the holder of one CVR, if any, pursuant to the CVR agreement, in each case, subject to the terms applied to the corresponding Company RSU immediately prior to the Effective Time. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:30 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 185 | $75.36 | $13,941.60 |
DisclosureSEC source: 0000859737-26-000033 · form4.xml · nonDerivative · entry 1 Liddy Anne M. · CIK 0002061422 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,052 F1 · shares: Shares withheld for tax obligations in connection with the settlement of restricted stock units for which service-based vesting requirements have been satisfied. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:16 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 337 | $74.15 | $24,988.55 |
DisclosureSEC source: 0000859737-25-000076 · form4.xml · nonDerivative · entry 1 Liddy Anne M. · CIK 0002061422 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,237 F1 · shares: Shares withheld for tax obligations in connection with the settlement of restricted stock units for which service-based vesting requirements have been satisfied. Read SEC document |
| November 11, 2025 Filed Nov 12, 2025 21:18 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 406 | $74.60 | $30,287.60 |
DisclosureSEC source: 0000859737-25-000048 · form4.xml · nonDerivative · entry 3 Liddy Anne M. · CIK 0002061422 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,574 F2 · balance_after: Includes 346 shares acquired pursuant to the Issuer's employee stock purchase plan since the date of the Reporting Person's most recently filed Form 4. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:18 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 17,496 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000859737-25-000048 · form4.xml · nonDerivative · entry 2 Liddy Anne M. · CIK 0002061422 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,980 F3 · shares: Represents restricted stock units which vest in equal installments on each of the first three anniversaries of the grant date, November 10, 2025. F4 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. F2 · balance_after: Includes 346 shares acquired pursuant to the Issuer's employee stock purchase plan since the date of the Reporting Person's most recently filed Form 4. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:18 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 288 | $74.10 | $21,340.80 |
DisclosureSEC source: 0000859737-25-000048 · form4.xml · nonDerivative · entry 1 Liddy Anne M. · CIK 0002061422 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,484 F1 · shares: Shares withheld for tax obligations in connection with the settlement of restricted stock units for which service-based vesting requirements have been satisfied. F2 · balance_after: Includes 346 shares acquired pursuant to the Issuer's employee stock purchase plan since the date of the Reporting Person's most recently filed Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.